AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Linzess/Constella (linaclotide) by Year
Linzess/Constella (linaclotide) — U.S. net revenues ($M) ($M)
AbbVie Linzess/Constella (linaclotide): $864M in FY2025, down 5.7% from a year earlier.
Latest, FY2025
864
Period ended Dec 31, 2025
Change on a year earlier
-5.7%
916 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Linzess/Constella (linaclotide) — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 864 | -5.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 916 | -14.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 1,073 | +7.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 1,003 | -0.3% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 1,006 | +55.0% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 649 | – | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-19) ↗ |
Cite this data
StockData. (2026). AbbVie Linzess/Constella (linaclotide) ($M), annual FY2018–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/linzess-us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.